After identifying one potential biomarker, we analyzed signaling properties affected by anti-IGF-1R treatment in various cell lines and evaluated expression status of the biomarker in 270 NSCLC patient samples. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.